Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 3
1982 6
1983 4
1984 4
1985 5
1986 4
1987 3
1988 3
1989 2
1990 8
1991 6
1992 5
1993 17
1994 13
1995 21
1996 22
1997 22
1998 13
1999 14
2000 8
2001 19
2002 18
2003 18
2004 10
2005 13
2006 17
2007 12
2008 18
2009 13
2010 26
2011 27
2012 40
2013 48
2014 34
2015 64
2016 71
2017 76
2018 82
2019 94
2020 92
2021 88
2022 80
2023 79
2024 31

Text availability

Article attribute

Article type

Publication date

Search Results

1,129 results

Results by year

Filters applied: . Clear all
Page 1
Tauroursodeoxycholic acid: a potential therapeutic tool in neurodegenerative diseases.
Khalaf K, Tornese P, Cocco A, Albanese A. Khalaf K, et al. Transl Neurodegener. 2022 Jun 4;11(1):33. doi: 10.1186/s40035-022-00307-z. Transl Neurodegener. 2022. PMID: 35659112 Free PMC article. Review.
In recent years, hydrophilic bile acids, particularly tauroursodeoxycholic acid (TUDCA), have shown important anti-apoptotic and neuroprotective activities, with numerous experimental and clinical evidence suggesting their possible therapeutic use as disease-modifie …
In recent years, hydrophilic bile acids, particularly tauroursodeoxycholic acid (TUDCA), have shown important anti-apoptotic a …
Gut microbiota mediates intermittent-fasting alleviation of diabetes-induced cognitive impairment.
Liu Z, Dai X, Zhang H, Shi R, Hui Y, Jin X, Zhang W, Wang L, Wang Q, Wang D, Wang J, Tan X, Ren B, Liu X, Zhao T, Wang J, Pan J, Yuan T, Chu C, Lan L, Yin F, Cadenas E, Shi L, Zhao S, Liu X. Liu Z, et al. Nat Commun. 2020 Feb 18;11(1):855. doi: 10.1038/s41467-020-14676-4. Nat Commun. 2020. PMID: 32071312 Free PMC article.
Administration of 3-indolepropionic acid, serotonin, short chain fatty acids or tauroursodeoxycholic acid shows a similar effect to IF in terms of improving cognitive function. ...
Administration of 3-indolepropionic acid, serotonin, short chain fatty acids or tauroursodeoxycholic acid shows a similar effe …
Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis.
Elia AE, Lalli S, Monsurrò MR, Sagnelli A, Taiello AC, Reggiori B, La Bella V, Tedeschi G, Albanese A. Elia AE, et al. Eur J Neurol. 2016 Jan;23(1):45-52. doi: 10.1111/ene.12664. Epub 2015 Feb 9. Eur J Neurol. 2016. PMID: 25664595 Free PMC article. Clinical Trial.
BACKGROUND AND PURPOSE: Tauroursodeoxycholic acid (TUDCA) is a hydrophilic bile acid that is produced in the liver and used for treatment of chronic cholestatic liver diseases. ...Secondary outcomes included between-treatment comparison of ALSFRS-R at study end, com …
BACKGROUND AND PURPOSE: Tauroursodeoxycholic acid (TUDCA) is a hydrophilic bile acid that is produced in the liver and used fo …
Bile acid metabolism is altered in multiple sclerosis and supplementation ameliorates neuroinflammation.
Bhargava P, Smith MD, Mische L, Harrington E, Fitzgerald KC, Martin K, Kim S, Reyes AA, Gonzalez-Cardona J, Volsko C, Tripathi A, Singh S, Varanasi K, Lord HN, Meyers K, Taylor M, Gharagozloo M, Sotirchos ES, Nourbakhsh B, Dutta R, Mowry EM, Waubant E, Calabresi PA. Bhargava P, et al. J Clin Invest. 2020 Jul 1;130(7):3467-3482. doi: 10.1172/JCI129401. J Clin Invest. 2020. PMID: 32182223 Free PMC article.
To mechanistically examine the implications of lower levels of bile acids in MS, we studied the in vitro effects of an endogenous bile acid, tauroursodeoxycholic acid (TUDCA), on astrocyte and microglial polarization. ...
To mechanistically examine the implications of lower levels of bile acids in MS, we studied the in vitro effects of an endogenous bile acid, …
NFATc1 signaling drives chronic ER stress responses to promote NAFLD progression.
Latif MU, Schmidt GE, Mercan S, Rahman R, Gibhardt CS, Stejerean-Todoran I, Reutlinger K, Hessmann E, Singh SK, Moeed A, Rehman A, Butt UJ, Bohnenberger H, Stroebel P, Bremer SC, Neesse A, Bogeski I, Ellenrieder V. Latif MU, et al. Gut. 2022 Dec;71(12):2561-2573. doi: 10.1136/gutjnl-2021-325013. Epub 2022 Apr 1. Gut. 2022. PMID: 35365570 Free PMC article.
Animals were fed with high-fat western diet (WD) alone or in combination with tauroursodeoxycholic acid (TUDCA), a candidate drug for NAFLD treatment. ...
Animals were fed with high-fat western diet (WD) alone or in combination with tauroursodeoxycholic acid (TUDCA), a candidate d …
Tauroursodeoxycholic acid inhibits intestinal inflammation and barrier disruption in mice with non-alcoholic fatty liver disease.
Wang W, Zhao J, Gui W, Sun D, Dai H, Xiao L, Chu H, Du F, Zhu Q, Schnabl B, Huang K, Yang L, Hou X. Wang W, et al. Br J Pharmacol. 2018 Feb;175(3):469-484. doi: 10.1111/bph.14095. Epub 2018 Jan 3. Br J Pharmacol. 2018. PMID: 29139555 Free PMC article.
Targeting the gut-liver axis and bile acid-based pharmaceuticals are potential therapies for NAFLD. The effect of tauroursodeoxycholic acid (TUDCA), a candidate drug for NAFLD, on intestinal barrier function, intestinal inflammation, gut lipid transport and microbio …
Targeting the gut-liver axis and bile acid-based pharmaceuticals are potential therapies for NAFLD. The effect of tauroursodeoxycholic …
Insights by which TUDCA is a potential therapy against adiposity.
Freitas IN, da Silva JA Jr, de Oliveira KM, Lourençoni Alves B, Dos Reis Araújo T, Camporez JP, Carneiro EM, Davel AP. Freitas IN, et al. Front Endocrinol (Lausanne). 2023 Feb 21;14:1090039. doi: 10.3389/fendo.2023.1090039. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 36896173 Free PMC article. Review.
Endoplasmic reticulum (ER) stress has been evidenced as a molecular hallmark of metabolic disorders. In this sense, the ER stress inhibitor tauroursodeoxycholic acid (TUDCA), a bile acid conjugated to taurine with chemical chaperone activity, has emerged as a therap …
Endoplasmic reticulum (ER) stress has been evidenced as a molecular hallmark of metabolic disorders. In this sense, the ER stress inhibitor …
Taurolithocholic acid but not tauroursodeoxycholic acid rescues phagocytosis activity of bone marrow-derived macrophages under inflammatory stress.
Wu S, Romero-Ramírez L, Mey J. Wu S, et al. J Cell Physiol. 2022 Feb;237(2):1455-1470. doi: 10.1002/jcp.30619. Epub 2021 Oct 27. J Cell Physiol. 2022. PMID: 34705285 Free PMC article.
Since bile acids regulate lipid metabolism and in some cases reduce inflammation, our second objective was to investigate whether myelin clearance could be improved with taurolithocholic acid (TLCA), tauroursodeoxycholic acid or hyodeoxycholic acid. In BMDM only TLC …
Since bile acids regulate lipid metabolism and in some cases reduce inflammation, our second objective was to investigate whether myelin cle …
Effects of Tauroursodeoxycholic Acid and 4-Phenylbutyric Acid on Selenium Distribution in Mice Model with Type 1 Diabetes.
Xing D, Zhou Q, Wang Y, Xu J. Xing D, et al. Biol Trace Elem Res. 2023 Mar;201(3):1205-1213. doi: 10.1007/s12011-022-03193-8. Epub 2022 Mar 18. Biol Trace Elem Res. 2023. PMID: 35303254 Free PMC article.
The effect of selenium on diabetes is significant. As pharmaceutical chaperones, tauroursodeoxycholic acid (TUDCA) and 4-phenylbutyric acid (4-PBA) can effectively improve the oxidative stress of the endoplasmic reticulum. ...
The effect of selenium on diabetes is significant. As pharmaceutical chaperones, tauroursodeoxycholic acid (TUDCA) and 4-pheny …
Potential therapeutic action of tauroursodeoxycholic acid against cholestatic liver injury via hepatic Fxr/Nrf2 and CHOP-DR5-caspase-8 pathway.
Song G, Weng F, Zou B, Zhao J, Jin J, Yan D, Huang K, Sun X, Liu C, Hu Y, Li Y, Qiu F. Song G, et al. Clin Sci (Lond). 2023 Apr 13;137(7):561-577. doi: 10.1042/CS20220674. Clin Sci (Lond). 2023. PMID: 36795945
Cholestasis is a pathophysiologic syndrome with limited therapeutic options. Tauroursodeoxycholic acid (TUDCA) has been employed to treat hepatobiliary disorders and is as effective as UDCA in alleviating cholestatic liver disease in clinical trials. ...
Cholestasis is a pathophysiologic syndrome with limited therapeutic options. Tauroursodeoxycholic acid (TUDCA) has been employ …
1,129 results